- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 19
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 19, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 19.
Number 5: A white paper from the Association for Accessible Medicines says that brand-name drug products are behind high prescription drug costs, and that those high costs endanger patients’ health.
Number 4: At last week’s 13th annual congress of the European Crohn's and Colitis Organisation, researchers presented findings from several studies investigating the efficacy of 2 biosimilar infliximab products.
Number 3: Investigators have released data from a 26-week open label extension of the NOR-SWITCH trial in patients with inflammatory bowel disease.
Number 2: The Patients for Biologic Safety and Access, a patient advocacy group, called on the FDA to revise its materials on biosimilars. However, some patient groups are calling PBSA’s stance into question.
Number 1: Express Scripts and Walgreens Boots are expanding their purchasing efforts to include specialty medications, such as biologics and biosimilars.
Also this week, contributor Amanda Forys, of Xcenda, explained what biosimilar manufacturers need to know about changes to the 340B Drug Pricing Program.
Finally, last week, our e-newsletter asked for your thoughts on when nonmedical substitution will become a reality in the United States.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
